SurModics Inc (SRDX) Stock
SRDX is no longer traded. SurModics was delisted from the Nasdaq in November 2025.
Prices on this page are historical; the last trade was November 18, 2025 at $42.98.
SurModics stock price history
SRDX final trading statistics
- Final close
- $42.98
- Final trading day
- Nov 18, 2025
- Market cap at delisting
- $614.51M
- Shares outstanding
- 14.30M
- Final 52-week range
- $25.87 – $43.00
- Avg. volume (final 3 mo.)
- 436,075
- All-time high (split-adj.)
- $80.35 · Sep 2018
- All-time low (split-adj.)
- $3.12 · Oct 1998
- Return since IPO
- +958.0%
- Beta
- 1.39
- Book value / share
- $7.79
- Price / book
- 5.52
SurModics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $126.08M | -$11.5M | -$0.39 |
| FY2023 | $132.58M | -$1.5M | $0.15 |
| FY2022 | $99.95M | -$27.3M | -$0.95 |
| FY2021 | $105.14M | $4.2M | $0.37 |
| FY2020 | $94.86M | $1.1M | $0.12 |
Last five fiscal years reported before the delisting; fiscal year ending September. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
SurModics stock FAQ
What happened to SurModics stock?
SurModics stock was delisted from the Nasdaq. Its final close was $42.98 on November 18, 2025.
Is SRDX stock still trading?
No. SRDX was delisted from the Nasdaq in November 2025 and no longer trades on a U.S. exchange.
What was the last price of SRDX stock?
SRDX closed at $42.98 on its final trading day, November 18, 2025, for a market value of about $614.51M.
What were SurModics's revenue and earnings in its last full fiscal year?
SurModics reported revenue of $126.08M and net income of -$11.5M in fiscal 2024, its last full year as a public company.
When did SurModics go public?
SurModics Inc stock began trading on March 4, 1998.